Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2024-03.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 82

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 83
Clinical effects of recombinant Korean growth hormone (LBD-003).

Journal of the Korean Pediatric Society 1991;34(8):1110-1115.
Published online August 31, 1991.
Clinical effects of recombinant Korean growth hormone (LBD-003).
Duk Hi Kim
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea
국내에서 합성된 성장호르몬 (LBD-003) 의 치료 효과
김덕희
연세대학교 의과대학 소아과학교실
Received: 4 June 1991   • Accepted: 8 July 1991
Abstract
LBD-003, methionyl GH, has been produced recently in the yeast by the use of recombinant method. The clinical efficacy and immunogenecity of LBD-003 were studied in 20 patients with naive GH deficiency. The subjects of this study were aged 5.1—13.9 years and received GH 1.5IU/kg thrice weekly for 1 year. During treatment, height, body weight & bone age were checked. Blood count, chemistry amd thyroid hormonal concentrations were checked, measurement of IGF-1 was done before and every 6 month and assay of antibody was performed before, 6 month and 12 month treatment. The height veloity was increased 8.55±2.28 cm/yr at 6 month & 7.22±1.46 cm/yr from 3.20±l. 21 cm/yr. The ratio of height age and bone age was 1.34 at 6 month and 1.31 at 1 year of therapy. The plasma IGF-1 levels rose significantly during treatment. No antibody against LBD-003 was observed in all patients. Thus, LBD-003 is very effective in stimulating linear growth in hGH deficiency.
Key Words: Short Stature, Growth Hormone Therapy


METRICS Graph View
  • 1,055 View
  • 16 Download